MedTrace Logo

Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer

NCT05332483 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-11-03

No results posted yet for this study

Summary

This is a single centre, single arm, open label, preoperative window of opportunity study. Grade 2 endometrioid endometrial carcinoma patients awaiting surgery will be prospectively recruited to receive a pre-operative progestin therapy course. Therapy response will be histologically evaluated and correlated with clinical and molecular data by comparison of responders vs. non-responders pre- and post-treatment tumor samples.

Conditions

Interventions

DRUG

Megestrol Acetate

Megestrol acetate, 160 mg daily (two 40mg tablets twice a day), for a minimum of 18 days.

Sponsors & Collaborators

  • Ontario Institute for Cancer Research

    collaborator OTHER

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Bojana Djordjevic, MD · Sunnybrook Health Sciences Centre

  • Danielle Vicus, MD, MSc · Sunnybrook Health Sciences Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-05
Primary Completion
2023-10-12
Completion
2023-10-12

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05332483 on ClinicalTrials.gov